Pierre Lapalme

Pierre Lapalme has served on the INSYS Therapeutics Board of Directors since March 2011.

Mr. Lapalme has been serving as a member of the board of directors of BioMarin Pharmaceutical Inc. since January 2004. He has also sat as Chairman from June 2014 to June 2015. From 1995 until his retirement in 2003, he served as Chief Executive Officer for Ethypharm North America, a drug delivery company.

Mr. Lapalme has held numerous senior and management positions within the pharmaceutical industry in both Canada and the U.S. From 1979 until 1994, he served as President and CEO of Rhone Poulenc Pharma Canada and USA, and Senior Vice President of North America Ethicals Rhone Poulenc Rorer, which later merged to become Aventis and subsequently Sanofi Aventis.

He has also served as a board member of Fist Horizon Pharmaceutical/Sciele Pharma, as well as Chair of the board from 2000 to 2008. He has served on the board of the National Pharmaceutical council, and was a member of the board for the Pharmaceutical Manufacturers Association of Canada where he played a leading role in reinstituting patent protection for pharmaceuticals in Canada. Mr. Lapalme currently serves on the boards of several biotech companies including Aeterna Zentaris.

Pierre Lapalme studied at the University of Western Ontario and INSEAD France. 

Investors

We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care and therapeutic products.

 

Investors

We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care and therapeutic products.